.jpg)
Boston Scientific's board approved a company-wide restructuring on 21 July, disclosed in a regulatory filing with the US Securities and Exchange Commission. The plan, formally named the 2026 Restructuring Plan, is framed as a response to challenges among key revenue drivers, and is designed to streamline operations and align resources with the company's strategic priorities.
The restructuring involves supply chain optimisation, moving certain production lines between facilities, and broader organisational changes. Implementation is set to begin this year and continue through 2029.
The company confirmed that headcount reductions are expected, even as it said it will continue hiring in areas where it is growing and shifting resources to meet global market demand. Employee impact plans will be developed region by region, in consultation with representative bodies where required under local laws.
The financial scale is significant. The filing estimates total pre-tax charges of $700 million to $800 million, with $600 million to $700 million in cash outlays. Termination benefits alone are projected at $275 million to $300 million. Once fully implemented, the programme is expected to reduce gross annual pre-tax expenses by approximately $500 million, with a substantial portion of that saving reinvested into strategic growth initiatives rather than returned as slack in the system.
Boston Scientific is scheduled to post its second-quarter results on 29 July, with investor attention focused on the performance of its heart device portfolio.
